Dan Salvo, Author at Forge Biologics

Forge Biologics Announces Closing of $120 Million Series B Financing

Posted on April 29, 2021 (April 29, 2021)

Financing led by RA Capital Managementwith participation from Perceptive Advisors, Surveyor Capital (a Citadel company), Octagon Capital, Marshall Wace, and […]

Forge Biologics to Present at Chardan’s 5th Annual Genetic Medicines Manufacturing Summit

Posted on April 22, 2021 (June 15, 2021)

COLUMBUS, OHIO April 22, 2021 – Forge Biologics, a hybrid gene therapy contract manufacturing, and clinical stage therapeutic development company, […]

Forge Biologics to Present at 2021 Virtual Cell and Gene Meeting on the Mediterranean

Posted on April 6, 2021 (June 15, 2021)

COLUMBUS, OHIO April 6, 2021 – Forge Biologics, a cGMP manufacturing and development company, announced today that Timothy J. Miller, […]

FDA Fast Track, ODD, and RPDD Designations for FBX-101 Gene Therapy for Patients with Krabbe Disease

Posted on February 16, 2021 (April 29, 2021)

The FDA has granted Fast Track Designation, Rare Pediatric Disease Designation, and Orphan Drug Designation to FBX-101 for treatment of patients […]

United Leukodystrophy Foundation

Posted on January 27, 2021 (April 29, 2021)

We’re pleased to share that the United Leukodystrophy Foundation has shared our press release, marking yet another avenue of informing […]

VIDEO: Manufacturing Capabilities

Posted on January 25, 2021 (April 29, 2021)

We are passionate about serving our clients by providing the highest quality vector and leading the industry in technological advancements. […]

“Building Better” Blog: Forge Biologics Spotlight

Posted on January 22, 2021 (April 29, 2021)

We are thrilled to have a spotlight in National Venture Capital Association‘s (NVCA) Building Better blog series alongside Molly (McCartin) Bonakdarpour of Drive […]